Augmentation of cardiac function in end-stage heart failure by combined use of dobutamine and amrinone.
A patient with end-stage congestive cardiomyopathy had progressive hemodynamic deterioration while awaiting orthotopic heart transplantation. Attempts to support cardiovascular function by high-dose dobutamine infusions were complicated by life-threatening cardiac arrhythmias. The addition of the noncatecholamine inotropic agent, amrinone, improved ventricular performance, enabling reduction of the dose of dobutamine and resolution of the cardiac arrhythmias. Beta receptor stimulation by dobutamine combined with phosphodiesterase inhibition by amrinone may additively or synergistically augment cardiac function despite severe congestive heart failure and also have an adrenergic "sparing effect."
D000631:Aminopyridines / Q000627:therapeutic use*; D000676:Amrinone; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004280:Dobutamine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged
D000631:Aminopyridines; D002316:Cardiotonic Agents; D004280:Dobutamine; D000676:Amrinone